Skye Bioscience Appoints Puneet S. Arora, MD, as Chief Medical Officer
Skye Bioscience (Nasdaq: SKYE) has appointed Dr. Puneet S. Arora as Chief Medical Officer. Dr. Arora, a board-certified physician in endocrinology, diabetes, and metabolism, brings over 15 years of experience in clinical trial design and execution. His appointment comes as Skye initiates its Phase 2 CBeyond™ obesity clinical trial for nimacimab, a differentiated CB1 inhibitor.
Dr. Arora's expertise in metabolic diseases and his track record in drug development are expected to be valuable assets for Skye. The company aims to leverage his knowledge to advance treatments that can significantly improve health outcomes, particularly in the field of obesity therapeutics.
In connection with Dr. Arora's appointment, Skye granted him a stock option to purchase 225,000 shares of common stock under the company's 2024 Inducement Equity Incentive Plan.
Skye Bioscience (Nasdaq: SKYE) ha nominato Dr. Puneet S. Arora come Chief Medical Officer. Il Dr. Arora, medico certificato in endocrinologia, diabete e metabolismo, porta con sé oltre 15 anni di esperienza nella progettazione e nell'esecuzione di studi clinici. La sua nomina arriva mentre Skye avvia il suo trial clinico di Fase 2 CBeyond™ per il nimacimab, un inibitore differenziato del CB1.
Si prevede che l'expertise del Dr. Arora nelle malattie metaboliche e il suo percorso nello sviluppo di farmaci saranno risorse preziose per Skye. L'azienda mira a sfruttare le sue conoscenze per avanzare trattamenti che possano significamente migliorare i risultati di salute, in particolare nel campo delle terapie per l'obesità.
In relazione alla nomina del Dr. Arora, Skye gli ha concesso un'opzione su azioni per acquistare 225.000 azioni ordinarie nell'ambito del piano di incentivazione azionaria 2024 dell'azienda.
Skye Bioscience (Nasdaq: SKYE) ha nombrado al Dr. Puneet S. Arora como Director Médico. El Dr. Arora, un médico certificado en endocrinología, diabetes y metabolismo, aporta más de 15 años de experiencia en el diseño y ejecución de ensayos clínicos. Su nombramiento se produce mientras Skye inicia su ensayo clínico de Fase 2 CBeyond™ para nimacimab, un inhibidor CB1 diferenciado.
Se espera que la experiencia del Dr. Arora en enfermedades metabólicas y su historial en el desarrollo de fármacos sean activos valiosos para Skye. La compañía tiene como objetivo aprovechar su conocimiento para avanzar tratamientos que puedan mejorar significativamente los resultados de salud, especialmente en el campo de la terapéutica de la obesidad.
En relación con el nombramiento del Dr. Arora, Skye le otorgó una opción sobre acciones para comprar 225,000 acciones comunes bajo el Plan de Incentivo de Capital 2024 de la compañía.
스카이 바이오사이언스 (Nasdaq: SKYE)는 푸니트 S. 아로라 박사를 최고 의료 책임자로 임명했습니다. 아로라 박사는 내분비학, 당뇨병 및 대사 분야의 전문의로, 임상 시험 설계 및 실행에서 15년 이상의 경험을 가지고 있습니다. 그의 임명은 스카이가 니마시맙에 대한 2상 CBeyond™ 비만 임상 시험을 시작하면서 이루어졌습니다. 이는 차별화된 CB1 억제제입니다.
아로라 박사의 대사 질환에 대한 전문성과 약물 개발에 있어서의 경력은 스카이에 귀중한 자산이 될 것으로 기대됩니다. 회사는 그의 지식을 활용하여 비만 치료 분야에서 건강 결과를 상당히 개선할 수 있는 치료법을 발전시키는 것을 목표로 하고 있습니다.
아로라 박사의 임명과 관련하여, 스카이는 그에게 회사의 2024 유도 자본 인센티브 계획에 따라 225,000주에 대한 주식 선택권을 부여했습니다.
Skye Bioscience (Nasdaq: SKYE) a nommé Dr. Puneet S. Arora au poste de Directeur Médical. Le Dr Arora, médecin certifié en endocrinologie, diabète et métabolisme, apporte plus de 15 ans d'expérience dans la conception et l'exécution d'essais cliniques. Sa nomination intervient alors que Skye initie son essai clinique de Phase 2 CBeyond™ pour le nimacimab, un inhibiteur CB1 différencié.
L'expertise du Dr Arora en matière de maladies métaboliques et son parcours dans le développement de médicaments devraient être des atouts précieux pour Skye. L'entreprise vise à tirer parti de ses connaissances pour faire progresser des traitements susceptibles d'améliorer significativement les résultats de santé, notamment dans le domaine des thérapies contre l'obésité.
En lien avec la nomination du Dr Arora, Skye lui a accordé une option d'achat d'actions lui permettant d'acquérir 225 000 actions ordinaires dans le cadre du Plan d'Incentive en Capital 2024 de la société.
Skye Bioscience (Nasdaq: SKYE) hat Dr. Puneet S. Arora zum Chief Medical Officer ernannt. Dr. Arora, ein zertifizierter Arzt für Endokrinologie, Diabetes und Metabolismus, bringt über 15 Jahre Erfahrung in der Planung und Durchführung klinischer Studien mit. Seine Ernennung erfolgt, während Skye mit der Phase 2 CBeyond™ Adipositas-Studie für Nimacimab, einen differenzierten CB1-Inhibitor, beginnt.
Die Expertise von Dr. Arora in Bezug auf Stoffwechselerkrankungen und seine Erfolgsbilanz in der Arzneimittelentwicklung werden voraussichtlich wertvolle Ressourcen für Skye sein. Das Unternehmen plant, sein Wissen zu nutzen, um Therapien voranzubringen, die die Gesundheitsergebnisse, insbesondere im Bereich der Adipositastherapie, erheblich verbessern können.
Im Zusammenhang mit der Ernennung von Dr. Arora hat Skye ihm eine Aktienoption gewährt, um 225.000 Stammaktien im Rahmen des Equity Incentive Plans 2024 des Unternehmens zu kaufen.
- Appointment of experienced CMO with expertise in metabolic diseases
- Initiation of Phase 2 CBeyond™ obesity clinical trial for nimacimab
- Potential for nimacimab as a unique obesity therapeutic with positive safety and tolerability profile
- None.
SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced the appointment of Puneet S. Arora, MD, MS, FACE, as Chief Medical Officer (CMO).
“We are thrilled to welcome Dr. Puneet Arora as the Chief Medical Officer at Skye at this pivotal moment in our journey, particularly with the initiation of the Phase 2 CBeyond™ obesity clinical trial for nimacimab, our differentiated CB1 inhibitor,” said Punit Dhillon, Skye’s CEO and Chair. “Dr. Arora is well-regarded in the industry, brings extensive experience in designing and executing clinical trials across multiple therapeutic areas, and has significant expertise in metabolic diseases such as obesity. Our purpose is to advance treatments that can significantly improve health outcomes and we look forward to leveraging his medical knowledge and deep understanding of regulatory and clinical development strategies in the metabolic field as we work toward that goal.”
Puneet S. Arora, MD, MS, FACE, is a board-certified physician in endocrinology, diabetes and metabolism. His career includes serving as a physician-scientist, drug developer and executive leader with more than 15 years of experience in designing and executing all phases of clinical trials across multiple therapeutic areas, regulatory submissions, and medical affairs in addition to fundraising with small biotech and large pharma.
Dr. Arora was CMO at Lassen Therapeutics (“Lassen”), a clinical-stage development company in the immunology and inflammation space. Dr. Arora joined Lassen at the preclinical stage, where he built the initial strategy that took Lassen’s lead molecule into the clinic and assisted in raising Series B funding and selecting an indication to establish proof-of-concept, these initiatives ultimately leading to the launch of a global Phase 2 study with required regulatory approvals.
Dr. Arora previously served as Head of Clinical Development at Principia Biopharma, a Sanofi company, where he led clinical development strategy and the design and execution of clinical studies across the company’s portfolio. He also served as Senior Medical Director, Early Clinical Development and Clinical Team Leader, Inflammation/Cardiovascular-Metabolism, at Genentech Research and Early Development. His role included leading global programs in metabolism (diabetes and obesity) and NASH.
Dr. Arora has authored or co-authored multiple peer-reviewed publications in high quality journals and presented at international scientific meetings, amongst his many accolades and accomplishments. Dr. Arora received his medical degree from the All India Institute of Medical Sciences, completed his residency in internal medicine at the Southern Illinois University School of Medicine, held a fellowship in endocrinology, diabetes and metabolism at NYU, and earned a Master’s Degree in Clinical Research from the Mayo Clinic as part of the Clinical Scientist Training Program. He was also a fellow in advanced diabetes at the Mayo Graduate School of Medicine.
“I have been following Skye’s progress for the past year and believe nimacimab has unique potential as an obesity therapeutic,” said Dr. Arora. “CB1 inhibition has broad evidence that its distinct attributes could potentially provide longer term, healthier outcomes for those seeking weight loss. Within the class, nimacimab is differentiated not only by its positive safety and tolerability profile but also by its potential to meaningfully impact the lives of patients struggling with obesity. I look forward to executing Skye’s Phase 2 CBeyond™ obesity trial to assess nimacimab as a monotherapy and explore its impact in combination with a GLP-1RA, and helping create and implement a broad strategic development plan for obesity and other metabolic diseases.”
Approval of Inducement Awards
In connection with the appointment of Dr. Arora as Chief Medical Officer of the Company, on September 3, 2024, Skye granted Dr. Arora a stock option to purchase 225,000 shares of Skye’s common stock under the Company’s 2024 Inducement Equity Incentive Plan (the “2024 Inducement Plan”),
About Nimacimab
Nimacimab is a first-in-class humanized negative allosteric monoclonal antibody that inhibits CB1 signaling in the periphery as an inverse agonist. Inhibition of CB1 has shown anti-fibrotic, anti-inflammatory, and metabolic mechanisms of action with potential to address a broad range of diseases with unmet medical needs such as obesity, chronic kidney disease, and metabolic dysfunction-associated steatohepatitis (MASH).
In July 2024 Skye conducted an Obesity KOL event with key opinion leaders and Skye management which highlighted the mechanisms of peripheral CB1 inhibition and the attributes and potential role of nimacimab in the obesity therapeutic landscape. The presentation and a replay of the call are available on the Company’s website.
About Skye Bioscience
Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye is conducting a Phase 2 clinical trial (ClinicalTrials.gov: NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). For more information, please visit: www.skyebioscience.com. Connect with us on X and LinkedIn.
CONTACTS
Investor Relations
ir@skyebioscience.com
(858) 410-0266
LifeSci Advisors, Mike Moyer
mmoyer@lifesciadvisors.com
(617) 308-4306
Media Inquiries
LifeSci Communications, Michael Fitzhugh
mfitzhugh@lifescicomms.com
(628) 234-3889
FORWARD LOOKING STATEMENTS
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our product development, business strategy, the timing of clinical trials, the timing of receipt of interim and final data and the therapeutic potential of our therapeutic candidates. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management’s current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including “anticipated,” “plans,” “goal,” “focus,” “aims,” “intends,” “believes,” “can,” “could,” “challenge,” “predictable,” “will,” “would,” “may” or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment, and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Company’s periodic filings with the Securities and Exchange Commission, including in the “Risk Factors” section of Skye’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Except as expressly required by law, Skye disclaims any intent or obligation to update these forward-looking statements.
FAQ
Who is the new Chief Medical Officer of Skye Bioscience (SKYE)?
What is Skye Bioscience's (SKYE) current clinical trial focus?
What stock options were granted to Dr. Arora by Skye Bioscience (SKYE)?
What is nimacimab and how does it relate to Skye Bioscience (SKYE)?
